Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Viatris Plots January Investor Day To Flesh Out Longer-Term Roadmap

As The Street Awaits Details Of Post 2023 Investment And Strategy

Executive Summary

Viatris will host another investor day, to take place early in the new year, to discuss its 2022-23 and 2024+ plans. Management provided details during the company’s Q3 earnings call, as Viatris announced it was once again raising full-year financial targets.

You may also be interested in...



Viatris Reaches $264m EpiPen Settlement Agreement With Trial Imminent

Viatris has reached an agreement worth a little over a quarter-of-a-billion dollars to resolve one set of antitrust claims that it unlawfully withheld generic competition to its controversial EpiPen autoinjector. The charge appeared on Viatris’ 2021 P&L, which was detailed during a company investor day.

Offloading Biosimilars To Biocon ‘First Step’ Towards Viatris’ $9bn Target

After confirming rumors that it would offload its biosimilars unit to its long-term partner Biocon, Viatris has outlined plans to add to the expected cash proceeds with other divestments to complete on several strategic goals up to 2023. Bumping up R&D spending to facilitate complex generic launches is a continued priority for the company.

Viatris CEO Talks Integration, Roadmap And Interchangeable Biosimilars

As CEO Michael Goettler provides an update on the progress made by Viatris in its first year as a combined company, he also offers Generics Bulletin hints as to the detailed strategy that will be unveiled at the firm’s upcoming investor day and explains how biosimilars – including interchangeable Semglee (insulin glargine) – and complex generics are important components of the firm’s future growth plans.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

GB151400

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel